

It is time anti-CGRP monoclonal antibodies be considered first-line prophylaxis for migraine

Já é tempo de os anticorpos monoclonais anti-CGRP serem reconhecidos como profilaxia de primeira linha para a migrânea

Gabriel Taricani KUBOTA^{1,2}

ABSTRACT

The result of more than thirty years of research, anti-CGRP monoclonal antibodies are currently the state of the art for migraine preventive therapy. Their efficacy and safety, supported by an already large and growing body of evidence, are added by many other advantages: an early onset of action, favorable posology, negligible pharmacological interaction, and a broad-reaching efficacy in many challenging clinical contexts. When compared to standard prophylactics, these novel medications seem at least as efficacious, clearly more tolerable and, consequently, with a superior adherence profile. Furthermore, recently published analyses indicate that they are cost-effective, especially among those with chronic migraine. Yet, current guidelines endorse their use only after multiple other preventives have failed or have been deemed not tolerable. Although this recommendation may have been sensible at first, the now available data strongly point that time has come for anti-CGRP monoclonal antibodies to be acknowledged as first-line treatments for migraine patients with severe disability. For these individuals, delaying treatment until several other alternatives have failed incurs in significant losses, both economically and to many relevant aspects of their lives.

Keywords: Migraine Disorders; Antibodies, Monoclonal; Calcitonin Gene-Related Peptide Receptor Antagonists; Cost-Benefit Analysis.

RESUMO

Frutos de mais de 30 anos de pesquisa, os anticorpos monoclonais anti-CGRP são atualmente o que há de mais moderno no tratamento preventivo da migrânea. À sua eficácia e segurança, já bem estabelecidos por um grande corpo de evidências, acrescentam-se outras vantagens: um início precoce de ação, posologia favorável, mínima interação farmacológica, e eficácia comprovada em uma variedade de contextos clínicos frequentemente desafiadores. Quando comparados a outros profiláticos, estas medicações aparentam ser ao menos tão eficazes, evidentemente mais toleráveis e, portanto, com melhor perfil de adesão. Ademais, estudos recentemente publicados indicam que elas são custo-efetivas, especialmente entre pacientes com migrânea crônica. Ainda assim, as diretrizes atuais orientam o seu uso apenas caso haja refratariedade ou intolerância a múltiplos outros preventivos. Apesar de esta recomendação poder ter sido sensata *a priori*, os dados disponíveis atualmente corroboram que já é tempo de estes anticorpos monoclonais serem reconhecidos como tratamentos de primeira linha para a migrânea associada à incapacidade grave. Para estes pacientes, demorar a oferecer este tratamento até que outras múltiplas alternativas tenham falhado, leva a perdas significativas, tanto economicamente quanto em múltiplos outros aspectos relevantes das suas vidas.

Palavras-chave: Transtornos de Enxaqueca; Anticorpos Monoclonais; Antagonistas do Receptor do Peptídeo Relacionado ao Gene de Calcitonina; Análise Custo-Benefício.

INTRODUCTION

Since the role of calcitonin gene-related peptide (CGRP) in migraine pathophysiology was first proposed in 1985, research in this field have come a long way, culminating in the publishing of the encouraging results of anti-CGRP monoclonal antibodies (anti-CGRP mAb) phase 3 trials in 2017, and the introduction

of these medications in the American and European markets in the following years^{1,2}. It should be highlighted that this was not only a major milestone in the clinical management of migraine but, from a historical standpoint, it was a revolution in the framework of migraine therapeutic development³. Indeed, until then, most advances in pharmacological prophylaxis for this condition had resulted from sheer serendipity, i.e.,

¹Universidade de São Paulo, Faculdade de Medicina, Hospital das Clínicas, Departamento de Neurologia, São Paulo SP, Brazil.

²Instituto do Câncer do Estado de São Paulo, São Paulo SP, Brazil.

GTK  <https://orcid.org/0000-0001-7790-8111>

Correspondence: Gabriel Taricani Kubota; Email: gabriel.kubota@hc.fm.usp.br.

Conflict of interest: There is no conflict of interest to declare.

Authors contributions: GTK: was responsible for the literature review, writing and reviewing of the manuscript.

Received on March 18, 2022; Accepted on April 29, 2022.



from repurposing drugs *a priori* developed for other diseases, such as hypertension, epilepsy or mood disorders, for migraine treatment, largely based on clinical empiricism⁴. Conversely, by targeting a specific molecule closely linked with its pathophysiology, anti-CGRP mAbs marked the dawn of the precision medicine era for migraine prophylaxis.

The clinical significance of the “target-based” properties of these medications can be observed in data stemming from the many clinical trials and prospective cohorts published since. While retaining an efficacy which is at least similar to that of other well-established drug prophylaxis, they have shown to deliver a much-improved tolerability and safety profile^{5,6}. That is not to mention a streak of very significant other advantages, including an early onset effect; favorable posology^{7–9}; negligible pharmacological interaction¹⁰; and a wide-range efficacy in many challenging clinical contexts such as medication-overuse headache (MOH), menstrually-related and multidrug resistant migraine^{11–14}.

However, in spite of all these advantages, recent guidelines on this topic seem to be less than encouraging when it comes to incorporating anti-CGRP mAbs into daily clinical practice. In fact, currently, both the American Headache Society and the European Headache Federation recommend the introduction of these medications only after at least 2 other well-established prophylaxis have failed or have been found to be not tolerable^{15,16}. While this caution may have been well justified at first, would the mounting favorable evidence and clinical experience gathered from the past 5 years not suffice to recommend their use as first-line treatment now?

WHAT IS EXPECTED FROM A FIRST-LINE THERAPY?

Firstly, it is important to acknowledge that making recommendations on medical treatments is no simple task. At first glance, the core concept behind any recommendation seems quite straightforward: deciding on the balance between the desirable and undesirable effects of a given intervention¹⁷. Certainly, the quantity and quality of the available body of evidence regarding their efficacy and safety plays an important role in this decision. In this sense, standardized methods for the assessment of evidence, such as the GRADE framework, have been developed and are widely used¹⁸.

However, if quality of evidence (QoE) was all it took, the sheer number of well-designed large, multicenter, double-blind clinical trials pointing to the significant efficacy and tolerability of anti-CGRP mAbs would render this discussion pointless. QoE, in fact, only reflects the certainty to which the available data regarding an intervention is consistent and generalizable. This is indeed an important aspect of a recommendation, but not the only one, and frequently not even the most important¹⁷.

Indeed, the decision on whether a certain treatment should be considered first-line for a given disease must also encompass:


the nature of the benefits and risks of this treatment, and their significance for the main stakeholders; the expected size of its beneficial effects; the cost-effectiveness; the potential impact on reducing health inequities; how it fares when compared to other available therapies; and its feasibility and acceptability¹⁷. Noticeably, current evidence supports that anti-CGRP mAbs fulfill all of the above criteria.

WHAT BENEFITS ARE EXPECTED FROM ANTI-CGRP MABS?

All pivotal placebo-controlled trials of erenumab (STRIVE, ARISE and Tepper *et al.*, 2017)^{19–21}, fremanezumab (HALO EM and HALO CM)^{22,23}, galcanezumab (EVOLVE-1&2 and REGAIN)^{24–26} and eptinezumab (PROMISE 1&2)^{27,28} reached their primary endpoint of reducing monthly migraine days (MMD) for both episodic (EM) and chronic migraine (CM). This indicates an overall class benefit due to their shared mechanism of action in blocking CGRP pathway. Criticism may arise from the apparent small effect size obtained for this endpoint, which ranged from 1.3 to 4.6 and from 1.7 to 2.6 MMD for EM and CM, respectively. However, it should be noticed that these values fall in line with those observed in most previous trials for well-established first-line migraine therapies, i.e., onabotulinumtoxin A, topiramate, valproate and candesartan. Furthermore, 50% response rates (i.e. proportion of subjects who achieved $\geq 50\%$ reduction in MMD frequency), a more palpable measure of the clinical utility of a prophylactic intervention, ranged approximately from 40 to 60% and from 30 to 60% for EM and CM, respectively (Figure 1).

Besides reducing migraine frequency, anti-CGRP mAbs produced relevant benefits in a series of patient-reported outcome measures. For example, among EM and CM subjects who completed the 52-week HALO fremanezumab extension study, large proportions reported improved anxiety (67.9%) and depression (64.7%) levels, better sleep quality (56.7%), better work/school performance (85.4%), better quality of time spent with family/friends (83%) and more enjoyment from leisure activities (81%)²⁹. Improvements in functionality and quality of life measures have also been reported in erenumab and galcanezumab trials^{30,31}.

Furthermore, open-label studies have demonstrated that these benefits are maintained in the long run. A 5-year prospective cohort with 383 EM patients treated with erenumab observed that reductions in MMD were retained throughout the follow-up, as well as the improvements in disability, headache impact and migraine-specific quality of life measures³². Of notice, this study found a 50% response rate in 71% at the 5-year follow-up, and that 35.5% had complete remission of their MMD³². These findings were also supported by those of other 12-month open-label cohorts with galcanezumab^{33,34} and a 12-month randomized trial with fremanezumab³⁵.



This chart summarizes the available data for the response rates found in the pivotal randomized clinical trials of erenumab (STRIVE, ARISE and Tepper *et al*, 2017)^{19–21}, fremanezumab (HALO EM and HALO CM)^{22,23}, galcanezumab (EVOLVE-1&2 and REGAIN) (24–26) and eptinezumab (PROMISE 1&2)^{27,28}.

Figure 1. Results for the 50%, 75% and 100% response rates of the pivotal trials of anti-CGRP monoclonal antibodies for migraine treatment. A: episodic migraine; B: chronic migraine.

CAN ANTI-CGRP MABS REDUCE INEQUITIES IN MIGRAINE MANAGEMENT?

Another very positive aspect of this medication class is its ability to deliver the above mentioned benefits to groups of subjects who typically fare poorly with current standard-of-care drug prophylaxis. For example, among the subset of migraineurs with medication-overuse headache (MOH), post-hoc analysis of the pivotal trials for erenumab³⁶, galcanezumab³⁷, fremanezumab³⁸ and eptinezumab³⁹ showed that their efficacy in reducing MMD was retained, and remained similar to that observed for non-MOH patients. Moreover, in a prospective 6-month real-life cohort including 139 CM patients (71.2% with MOH), treatment with erenumab or galcanezumab resulted in similar 50% response rates for MMD reduction both in MOH (63.6%) and non-MOH (57.5%; $p=0.50$) subjects¹¹. Very interestingly, although 60.6% of the MOH patients ceased to fulfill criteria for this condition at the end of this study, no detoxication protocol nor education to stop acute medication were administered prior to anti-CGRP mAb treatment¹¹. Also, in another post-hoc analysis, the subset of EM patients with menstrually-related migraine enrolled in STRIVE was shown to benefit similarly to those without this condition from erenumab treatment¹².

Anti-CGRP mAb treatment also may herald hope for those who were refractory to multiple well-established prophylaxis, or are unable to tolerate them. This specific subset of patients has been directly examined in phase 3b clinical trials for erenumab (LIBERTY)¹³, galcanezumab (CONQUER)⁴⁰, fremanezumab (FOCUS)⁴¹ and eptinezumab (DELIVERY)⁴². These studies included EM and/or CM subjects who had failed or were deemed unable to tolerate 2 to 4 standard drug prophylaxis. As with the pivotal trials for these medications, all of them reached their primary endpoints of reduction in MMD. What is more, the achieved magnitude of effect for 50% response rate ranged approximately from 30% to 50%. These are very promising figures for such a challenging group of patients, especially when considered the lower than usual placebo effect found in these trials.

Additionally, anti-CGRP mAbs may also benefit subjects who have failed the only available first-line parenteral migraine prophylaxis: onabotulinumtoxin A. A real-life prospective cohort including 150 subjects who had partial or no significant response to onabotulinumtoxin A, found that a 3-month treatment with galcanezumab or erenumab resulted in a 50% response rate of around 50% in MMD reduction⁴³. Results from a post-hoc analysis of the pivotal galcanezumab trials also supported these findings⁴⁴.

WHAT ARE THE OTHER ADVANTAGES OF ANTI-CGRP MABS?

Besides the many already mentioned benefits that these medications bring to the table, they also offer other very relevant advantages. The most important one, perhaps, is its favorable posology and adherence profile. Indeed, oral migraine prophylaxis is frequently hindered by high drop-out rates, even at medium-term follow-up. A systematic review of observational and clinical trials with propranolol, amitriptyline and topiramate found that adherence rates varied from 21 to 80% at 6 months, and from only 35 to 56% at 1 year⁴⁵. Adverse events were the most common cause for discontinuation⁴⁵. This major drawback for migraine therapy was initially tackled by the introduction of the parenteral treatment with onabotulinumtoxin A for CM, administered quarterly. Randomized trials with this medication found drop-out rates as low as 2 to 3%⁵. Likewise studies with anti-CGRP mAbs, administered parenterally monthly or quarterly, observed very low discontinuation rates ranging from 0 to 4% (Figure 2).

Another advantage is the rapid onset with which anti-CGRP mAbs provide their effect. While conventional oral drug prophylaxis require weeks to deliver improvements in migraine, mounting evidence indicates that significant benefits can be observed as early as in the first day of therapy for galcanezumab⁷, and in the first week for erenumab⁹ and fremanezumab^{8,46}. Of special interest, besides its established efficacy in reducing MMD, eptinezumab has also been shown to be useful in treating acute migraine attacks. In a recently published randomized trial, it resulted in significantly superior headache pain freedom and resolution of the most bothersome symptom rates as early as 2 hours after infusion, when compared to placebo⁴⁷.


Finally, anti-CGRP mAbs have a very favorable pharmacokinetic profile. Instead of being metabolized by liver enzymes,

these medications are cleared by general proteolytic degradation pathways¹⁰. This reduces significantly the risk for clinically significant pharmacological interaction with other drugs, such as antiepileptics, anticoagulants and hormonal contraceptives.

DO WE HAVE ENOUGH DATA ABOUT ANTI-CGRP MABS SAFETY?

Long before the publishing of the results of the first phase 3 trials of anti-CGRP mAbs, reasonable concerns were raised regarding the risks of interfering in the CGRP pathway. This is because CGRP has been shown to play significant roles in many physiologic processes, especially: inflammation, wound healing, vasodilatation and insulin release and resistance⁴⁸. However, it must be highlighted that this molecule is not the only one implied in these processes, nor are anti-CGRP mAbs able to completely block its pathway. In fact, rimegepant (a small molecule CGRP receptor antagonist) has been observed to be effective in treating acute migraine attacks even in the setting of erenumab treatment⁴⁹, indicating that a significant CGRP pathway activity persists in spite of the use of this mAb.

Despite these concerns, the only adverse reaction that has been consistently found to be statistically more frequent with anti-CGRP mAbs in the high-quality placebo-controlled trials that have since been published are of local nature, i.e. injection-site pain, erythema and pruritus⁵⁰. It is important to highlight that these adverse reactions were generally mild-to-moderate in severity, did not increase with the number of doses received, and very rarely led to treatment discontinuation⁵¹. An exception is made for erenumab trials, which also reported a higher frequency of constipation when the 140 mg dose was administered. However, this collateral effect was also described to have been mild to moderate and easily managed⁵². Moreover, its frequency reduced significantly throughout the long-term



Data from Vandervorst *et al.*, 2021 (5).

Figure 2. Discontinuation rates in randomized clinical trials of pharmacological migraine prophylactic treatments.

open-label extension phases of these studies⁵². It should be highlighted that erenumab safety has been assessed in a 5-year open-label extension study that enrolled subjects who had participated in a phase 2 randomized trial with this medication for EM^{32,53}. This was one of the longest cohorts to have ever been published among migraine prophylactic drugs, and it found no new safety signals, nor increased rates of adverse effects, in relation to the double-blind trial phase³². Furthermore, pooled results from 2 small double-blind placebo-controlled trials with eptinezumab showed that this medication was well tolerated and not associated with metabolic effects among overweight/obese patients, nor those who suffered from type 1 diabetes⁵⁴.

Post-marketing surveillance studies have also portrayed an overall reassuring picture so far. It must be acknowledged that the FDA Adverse Event Reporting System (FAERS) has identified post-marketing cases of possible association between erenumab and new-onset hypertension⁵⁵. This has led FDA to add a warning statement in the prescription label of erenumab in the United States. However, in the more than 1,300 migraine patients that were treated with erenumab in phase 2 and 3 randomized clinical trials, this adverse event has not been identified, nor any other significant cardiovascular collateral effect could have been attributed to this medication⁵⁶. What is more, when data from clinical trials and post-marketing surveillance studies are pooled together, the exposure-adjusted incidence of hypertension was as low as 0.144 per 100 patient-years⁵⁷.

DO ANTI-CGRP MABS WORK BETTER THAN OTHER MIGRAINE THERAPIES?

Although this is a very relevant topic, as in many other fields of Neurology, there is a lack of direct data from head-to-head trials that may help address it. However, so far available data supports a clear-cut advantage of anti-CGRP mAbs over standard first and second-line therapies.

To the best of my knowledge, the first and so far the only head-to-head trial to have compared an anti-CGRP mAb with a first-line migraine prophylaxis was HER-MES⁵⁸. This was a phase 4 double-blind randomized trial, with a double-dummy design, which compared topiramate (50-100mg/day) with erenumab (70-140mg/monthly), during a 6-month follow-up period. Its primary endpoint was the rate of medication discontinuation due to an adverse event, but 50% response rate was also examined. This trial enrolled 867 subjects, most of whom naïve to prior prophylactic treatment (59.8%) and with EM (88.9%)⁵⁸. Drop-out rates due to adverse events were significantly lower in the erenumab group (10.6%), compared to the topiramate one (38.9%; OR 0.19; $p < 0.001$). Also, in a modified intention-to-treat analysis, the 50% response rate for MMD reduction was significantly larger for erenumab (55.4%) than topiramate (31.2%; OR 2.76; $p < 0.001$)⁵⁸. Although discontinuation rates for erenumab were indeed larger than those reported in previous trials, as the authors have pointed out, this may have been justified by a placebo effect resulting from the double-dummy

design⁵⁸. Of note, topiramate is currently considered one of the most efficacious prophylactics, and the oral one with highest level of evidence for CM treatment^{59,60}.

Besides HER-MES, comparison with other standard preventive medications has been made through indirect comparison studies^{5,6,61}. One of the most broad-reaching of these, by Vandevorst *et al*, included phase 2 and 3 trials of all 4 available anti-CGRP mAbs, and of currently well-established prophylactics (including topiramate, valproate, beta-blockers, candesartan and onabotulinumtoxin A)⁵. It showed that, as a class, anti-CGRP mAbs appear to be clearly superior in terms of tolerability, and at least as efficacious (and possibly more so) than other first-line treatments⁵. QoE was also generally higher for this novel medication class than for the others⁵.

Finally, anti-CGRP mAbs also have advantages over onabotulinumtoxin A, a parenteral alternative with similar cost and widely considered first-line therapy for CM^{16,59}. On one hand, indirect comparison studies between pooled randomized trials of these medications have suggested similar effectiveness for CM^{5,61}. On the other, as aforementioned, some studies have demonstrated that anti-CGRP mAb treatment may reduce significantly MMD among subjects who had previously fared poorly with onabotulinumtoxin A^{43,44}. Onabotulinumtoxin A has not been shown to provide consistent benefits for EM, differently than anti-CGRP mAbs⁶². Additionally, controversy still remains about the efficacy of onabotulinumtoxin A in treating CM associated with MOH⁶³.

Moreover, there are some other practical advantages to this parenteral counterpart that should be mentioned. Firstly, anti-CGRP mAbs administration, made though a single injection, is less uncomfortable than the 31 to 39-injection PREEMPT protocol. Moreover, onabotulinumtoxin A is applied in the cephalic and neck segments, including frequently tender regions and areas in which migraine-induced scalp allodynia occurs. Conversely, erenumab, fremanezumab and galcanezumab are administered in distant sites, subcutaneously. Additionally, performing the PREEMPT protocol requires a specifically trained healthcare provider. Accessibility to such professionals may be limited in some locations, or under certain contexts. One recent example was the COVID-19 pandemic, during which lockdown and other sanitary measures led to the interruption of the activities of many headache clinics where onabotulinumtoxin A was administered; and discouraged many to come to the overwhelmed healthcare services to receive it. This resulted in significant delays in the treatment with this medication, and increased headache frequency^{64,65}. Contrastingly, aside from eptinezumab (which is administered by intravenous infusion), anti-CGRP mAbs are self-administered with ease, and require very little training.

A MATTER OF BURDEN

At this point, there should probably remain very few strong arguments against offering anti-CGRP mAbs as first-line

treatment for migraine. Except for a key aspect: price. And indeed, while the cost of these novel medications may vary across different locations, it is several times more expensive than any other oral prophylactics. Their prices, however, generally fall in line with those of onabotulinumtoxin A. Given that roughly 14% of the worldwide population suffers with migraine⁶⁶, one could argue it would not be viable to promptly offer it as a first line treatment to all.

While that might seem sensible at first glance, it is also a gross simplification of the problem. Indeed, when deciding on a treatment, one should not only consider its cost, but also the burden imposed by the disease, as well as the effectiveness of the treatment in reducing it. And, though frequently neglected, the burden of migraine is not a small one. Primary headaches are currently the second major cause of disease-related disability worldwide, largely due to migraine⁶⁷. Migraine in itself is the single most important cause of disability among all neurologic diseases, the sheer number of years lived with disability it results in being larger than that produced by stroke, dementia, Parkinson's disease and multiple sclerosis summed together⁶⁷. This, of course, comes with a price.

In 2014 it was estimated that migraineurs had an incremental US\$ 8,924.00 cost to health insurance services annually, when compared to matched controls in the United States (US)⁶⁸. Most of this resulted from direct costs, including outpatient pharmacy, physician visits, brain imaging and hospitalizations⁶⁸. In Italy, direct annual expenditures due to migraine were estimated in € 1,482.00 *per capita*. The distribution of these costs, evidently, is not homogeneous. Annual direct cost of CM is estimated to be 4.8-fold higher than for EM⁶⁸. Furthermore, among MOH patients, two thirds of whom have migraine⁶⁹, annual direct and indirect *per capita* costs soar up to € 10,533.00 in Italy⁷⁰.

Besides health-related costs, migraine severely hinders work productivity. On average, CM patients lose 4.6 work hours per week due to headache⁷¹. Collectively, due to presenteeism and absenteeism, migraine results annually in losses amounting to US\$ 21.3 billion in Japan⁷², £ 8.8 billion in U.K. and € 122 billion in Germany⁷³. In Brazil, the economic burden due to headache-related presenteeism and absenteeism (mostly migraine), was recently estimated in R\$ 67.6 billion annually⁷⁴. Individually, it also exacts a sizable cost to the career and professional life of some. CM patients were found to be 19% less likely to be working for pay, when compared to low-frequency EM ones⁷¹. In the CaMEO study, a landmark prospective longitudinal cohort which assessed migraine epidemiology and burden among 13,064 subjects, around two thirds of CM patients reported that this disease had interfered in their careers⁷⁵. In this research, among CM subjects: 15.2% admitted to feeling a burden to coworkers, 14% to having chosen less demanding jobs, 10.8% claimed to earn less/have missed a raise, and 9.8% felt that their career advancement had been limited due to migraine⁷⁵. Unfortunately, in *My Migraine Voice*, another observational study with 11,266 migraineurs, 27% reported lack of understanding among work colleagues about their condition⁷⁶.

Migraine also very frequently results in losses to some things which cannot really be put a price on. For example, in the aforementioned *My Migraine Voice* study, 64% of respondents reported that the disease had undermined their private life, including: missing on important events such as birthdays and weddings (52%); effects on sex life (49%); avoiding making commitments (50%) and feeling guilty about the impact migraine has on their family (44%)⁷⁶. Moreover, 59% claimed not being able to participate in hobbies/activities they used to and 34% informed having been stopped from engaging in sports or exercise⁷⁶. This burdensome condition also takes a heavy toll on loved ones. In CaMEO study, spouses to CM patients reported reduced enjoyment of time spent with their partner (76.5%); feeling that the migraineur had significantly reduced involvement in family activities (62.3%); resenting having to do everything when the migraineur has a headache (23.4%); worrying about covering the household expenses (33.8%) and about having long-term financial security for their family (40.4%); and that they believed the migraineur would be a better parent if they did not have headaches (43.9%)⁷⁷. In the same study, adolescents to parents who suffered from CM had significantly higher levels of depression ($p=.08$) and anxiety symptoms ($p=.01$), compared to those whose parents suffered from EM⁷⁸. They were also more prone to feel they would get along better with their parents if they did not have headaches (43.5% vs. 21.5%, $p<.001$) and that their migraineur parent had let them down (26.8% vs. 13.4%, $p<.001$)⁷⁸.

In face of the overwhelming and wide-ranging burden migraine causes, it would not be surprising if cost-effectiveness analysis supported the use of anti-CGRP mAbs. And, in fact, they do. A recently published study weighted the overall cost of systematically prescribing erenumab to the whole indicated German population with the reduction in migraine days and corresponding productivity losses. It found that this would result in savings due to avoided productivity losses amounting to € 26.6 billion, at the incremental healthcare costs of only € 8.4 billion⁷³. In line with these results, another study with the US population observed that, even when only direct disease-related costs are considered, erenumab may be cost-effective for CM patients⁷⁹. In Switzerland, cost-effectiveness for this medication was also demonstrated for patients who had failed other prophylactics previously⁸⁰.

THE PRICE OF THE DELAY

All things considered, should anti-CGRP mAbs be acknowledged as a first-line therapy for migraine prevention? Modern individually-tailored clinical practice fortunately leaves little space to broad generalizations such as this. Indeed, although these medications are effective, tolerable and safe, their cost may limit their use for mild low-frequency EM. However, that is not the case for burdensome high-frequency EM and CM patients, especially those who suffer from MOH. For these individuals, delaying treatment until several other alternatives

with much slower onset of action, less tolerability, possibly less effectiveness and which are much less prone to be adhered to in the long run, have failed, as *per* current guidelines, has a price.

A steep price that will be exacted from both the society's and the patient's pockets, as well as from priceless things: quality of life, functionality, relationship with loved ones and dignity.

References

1. Tepper SJ. History and review of anti-calcitonin gene-related peptide (CGRP) therapies: from translational research to treatment. *Headache*. 2018 Nov;58 Suppl 3:238-75. <https://doi.org/10.1111/head.13379>
2. Edvinsson L, Haanes KA, Warfvinge K, Krause DN. CGRP as the target of new migraine therapies - successful translation from bench to clinic. *Nat Rev Neurol*. 2018 Jun;14(6):338-50. <https://doi.org/10.1038/s41582-018-0003-1>
3. Hargreaves R, Olesen J. Calcitonin gene-related peptide modulators - the history and renaissance of a new migraine drug class. *Headache*. 2019 Jun;59(6):951-70. <https://doi.org/10.1111/head.13510>
4. Ban TA. The role of serendipity in drug discovery. *Dialogues Clin Neurosci*. 2006;8(3):335-44. <https://doi.org/10.31887/DCNS.2006.8.3/tban>
5. Vandervorst F, Deun LV, Dycke AV, Paemeleire K, Reuter U, Schoenen J, et al. CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs. *J Headache Pain*. 2021 Oct 25;22(1):128. <https://doi.org/10.1186/s10194-021-01335-2>
6. Vereem LH, Raffaelli B, Mecklenburg J, Kelderman T, Neeb L, Reuter U. Indirect comparison of topiramate and monoclonal antibodies against CGRP or its receptor for the prophylaxis of episodic migraine: a systematic review with meta-analysis. *CNS Drugs*. 2021 Aug 1;35(8):805-20. <https://doi.org/10.1007/s40263-021-00834-9>
7. Detke HC, Millen BA, Zhang Q, Samaan K, Ailani J, Dodick DW, et al. Rapid onset of effect of galcanezumab for the prevention of episodic migraine: analysis of the EVOLVE studies. *Headache*. 2020 Feb;60(2):348-59. <https://doi.org/10.1111/head.13691>
8. Takeshima T, Nakai M, Shibasaki Y, Ishida M, Kim B-K, Ning X, et al. Early onset of efficacy with fremanezumab in patients with episodic and chronic migraine: subanalysis of two phase 2b/3 trials in Japanese and Korean patients. *J Headache Pain*. 2022 Feb 9;23(1):24. <https://doi.org/10.1186/s10194-022-01393-0>
9. Schwedt T, Reuter U, Tepper S, Ashina M, Kudrow D, Broessner G, et al. Early onset of efficacy with erenumab in patients with episodic and chronic migraine. *J Headache Pain*. 2018 Oct 1;19(1):92. <https://doi.org/10.1186/s10194-018-0923-6>
10. Szkutnik-Fiedler D. Pharmacokinetics, pharmacodynamics and drug-drug interactions of new anti-migraine drugs-lasmiditan, gepants, and Calcitonin-Gene-Related Peptide (CGRP) receptor monoclonal antibodies. *Pharmaceutics*. 2020 Dec 3;12(12):1180. <https://doi.org/10.3390/pharmaceutics12121180>
11. Caronna E, Gallardo VJ, Alpuente A, Torres-Ferrus M, Pozo-Rosich P. Anti-CGRP monoclonal antibodies in chronic migraine with medication overuse: real-life effectiveness and predictors of response at 6 months. *J Headache Pain*. 2021 Oct 7;22(1):120. <https://doi.org/10.1186/s10194-021-01328-1>
12. Pavlovic JM, Paemeleire K, Göbel H, Bonner J, Rapoport A, Kagan R, et al. Efficacy and safety of erenumab in women with a history of menstrual migraine. *J Headache Pain*. 2020 Aug 3;21(1):95. <https://doi.org/10.1186/s10194-020-01167-6>
13. Reuter U, Goadsby PJ, Lanteri-Minet M, Wen S, Hours-Zesiger P, Ferrari MD, et al. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study. *Lancet*. 2018 Nov 24;392(10161):P2280-7. [https://doi.org/10.1016/S0140-6736\(18\)32534-0](https://doi.org/10.1016/S0140-6736(18)32534-0)
14. Okonkwo R, Tockhorn-Heidenreich A, Stroud C, Paget M-A, Matharu MS, Tassorelli C. Efficacy of galcanezumab in patients with migraine and history of failure to 3-4 preventive medication categories: subgroup analysis from CONQUER study. *J Headache Pain*. 2021 Sep 30;22(1):113. <https://doi.org/10.1186/s10194-021-01322-7>
15. Sacco S, Bendtsen L, Ashina M, Reuter U, Terwindt G, Mitsikostas D-D, et al. European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. *J Headache Pain*. 2019 May 23;20(1):58. <https://doi.org/10.1186/s10194-019-0972-5>
16. Burch RC, Ailani J, Robbins MS. The American Headache Society consensus statement: update on integrating new migraine treatments into clinical practice. *Headache*. 2022 Jan;62(1):111-2. <https://doi.org/10.1111/head.14245>
17. Alonso-Coello P, Oxman AD, Moberg J, Brignardello-Petersen R, Akl EA, Davoli M, et al. GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 2: Clinical practice guidelines. *BMJ*. 2016 Jun 30;353:i2089. <https://doi.org/10.1136/bmj.i2089>
18. Balshem H, Helfand M, Schünemann HJ, Oxman AD, Kunz R, Brozek J, et al. GRADE guidelines: 3. Rating the quality of evidence. *J Clin Epidemiol*. 2011 Apr 1;64(4):401-6. <https://doi.org/10.1016/j.jclinepi.2010.07.015>
19. Dodick DW, Ashina M, Brandes JL, Kudrow D, Lanteri-Minet M, Osipova V, et al. ARISE: a phase 3 randomized trial of erenumab for episodic migraine. *Cephalalgia*. 2018 May 1;38(6):1026-37. <https://doi.org/10.1177/0333102418759786>
20. Goadsby PJ, Reuter U, Hallström Y, Broessner G, Bonner JH, Zhang F, et al. A controlled trial of erenumab for episodic migraine. *N Engl J Med*. 2017 Nov 30;377(22):2123-32. <https://doi.org/10.1056/NEJMoa1705848>
21. Tepper S, Ashina M, Reuter U, Brandes JL, Doležil D, Silberstein S, et al. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. *Lancet Neurol*. 2017 Jun 1;16(6):P425-34. [https://doi.org/10.1016/S1474-4422\(17\)30083-2](https://doi.org/10.1016/S1474-4422(17)30083-2)
22. Dodick DW, Silberstein SD, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T, et al. Effect of fremanezumab compared with placebo for prevention of episodic migraine: a randomized clinical trial. *JAMA*. 2018 May 15;319(19):1999-2008. <https://doi.org/10.1001/jama.2018.4853>
23. Silberstein SD, Dodick DW, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T, et al. Fremanezumab for the Preventive Treatment of Chronic Migraine. *N Engl J Med*. 2017 Nov 30;377(22):2113-22. <https://doi.org/10.1056/NEJMoa1709038>
24. Stauffer VL, Dodick DW, Zhang Q, Carter JN, Ailani J, Conley RR. Evaluation of galcanezumab for the prevention of episodic migraine: The EVOLVE-1 randomized clinical trial. *JAMA Neurol*. 2018 Sep 1;75(9):1080-8. <https://doi.org/10.1001/jamaneurol.2018.1212>
25. Skljarevski V, Matharu M, Millen BA, Ossipov MH, Kim B-K, Yang JY. Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 phase 3 randomized controlled clinical trial. *Cephalalgia*. 2018 Jul 1;38(8):1442-54. <https://doi.org/10.1177/0333102418779543>
26. Detke HC, Goadsby PJ, Wang S, Friedman DI, Seltzer KJ, Aurora SK. Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study. *Neurology*.

2018 Dec 11;91(24):e2211-21. <https://doi.org/10.1212/WNL.0000000000006640>

27. Ashina M, Saper J, Cady R, Schaeffler BA, Biondi DM, Hirman J, et al. Eptinezumab in episodic migraine: a randomized, double-blind, placebo-controlled study (PROMISE-1). *Cephalalgia*. 2020 Mar 1;40(3):241-54. <https://doi.org/10.1177/0333102420905132>
28. Lipton RB, Goadsby PJ, Smith J, Schaeffler BA, Biondi DM, Hirman J, et al. Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2. *Neurology*. 2020 Mar 31;94(13):e1365-77. <https://doi.org/10.1212/WNL.00000000000009169>
29. Buse DC, Gandhi SK, Cohen JM, Ramirez-Campos V, Cloud B, Yang R, et al. Improvements across a range of patient-reported domains with fremanezumab treatment: results from a patient survey study. *J Headache Pain*. 2020 Sep 4;21(1):109. <https://doi.org/10.1186/s10194-020-01177-4>
30. Ford J, Tassorelli C, Leroux E, Wang S, Ayer D, Nichols R, et al. Changes in patient functioning and disability: results from a phase 3, double-blind, randomized, placebo-controlled clinical trial evaluating galcanezumab for chronic migraine prevention (REGAIN). *Qual Life Res*. 2021 Jan;30(1):105-15. <https://doi.org/10.1007/s11136-020-02623-1>
31. Ailani J, Andrews JS, Rettiganti M, Nicholson RA. Impact of galcanezumab on total pain burden: findings from phase 3 randomized, double-blind, placebo-controlled studies in patients with episodic or chronic migraine (EVOLVE-1, EVOLVE-2, and REGAIN trials). *J Headache Pain*. 2020 Oct 17;21(1):123. <https://doi.org/10.1186/s10194-020-01190-7>
32. Ashina M, Goadsby PJ, Reuter U, Silberstein S, Dodick DW, Xue F, et al. Long-term efficacy and safety of erenumab in migraine prevention: results from a 5-year, open-label treatment phase of a randomized clinical trial. *Eur J Neurol*. 2021 May;28(5):1716-25. <https://doi.org/10.1111/ene.14715>
33. Hirata K, Takeshima T, Sakai F, Tatsuoka Y, Suzuki N, Igarashi H, et al. A long-term open-label safety study of galcanezumab in Japanese patients with migraine. *Expert Opin Drug Saf*. 2021 Jun;20(6):721-33. <https://doi.org/10.1080/14740338.2021.1866536>
34. Camporeale A, Kudrow D, Sides R, Wang S, Van Dycke A, Selzler KJ, et al. A phase 3, long-term, open-label safety study of galcanezumab in patients with migraine. *BMC Neurol*. 2018 Nov 9;18(1):188. <https://doi.org/10.1186/s12883-018-1193-2>
35. Goadsby PJ, Silberstein SD, Yeung PP, Cohen JM, Ning X, Yang R, et al. Long-term safety, tolerability, and efficacy of fremanezumab in migraine: a randomized study. *Neurology*. 2020 Nov 3;95(18):e2487-99. <https://doi.org/10.1212/WNL.0000000000010600>
36. Tepper SJ, Diener H-C, Ashina M, Brandes JL, Friedman DI, Reuter U, et al. Erenumab in chronic migraine with medication overuse: subgroup analysis of a randomized trial. *Neurology*. 2019 May 14;92(20):e2309-20. <https://doi.org/10.1212/WNL.00000000000007497>
37. Dodick DW, Doty EG, Aurora SK, Ruff DD, Stauffer VL, Jedynek J, et al. Medication overuse in a subgroup analysis of phase 3 placebo-controlled studies of galcanezumab in the prevention of episodic and chronic migraine. *Cephalalgia*. 2021 Mar 1;41(3):340-52. <https://doi.org/10.1177/0333102420966658>
38. Silberstein SD, Cohen JM, Seminerio MJ, Yang R, Ashina S, Katsarava Z. The impact of fremanezumab on medication overuse in patients with chronic migraine: subgroup analysis of the HALO CM study. *J Headache Pain*. 2020 Sep 21;21(1):114. <https://doi.org/10.1186/s10194-020-01173-8>
39. Diener H-C, Marmura MJ, Tepper SJ, Cowan R, Starling AJ, Diamond ML, et al. Efficacy, tolerability, and safety of eptinezumab in patients with a dual diagnosis of chronic migraine and medication-overuse headache: subgroup analysis of PROMISE-2. *Headache*. 2021 Jan;61(1):125-36. <https://doi.org/10.1111/head.14036>
40. Mulleners WM, Kim B-K, Láinez MJA, Lanteri-Minet M, Pozo-Rosich P, Wang S, et al. Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial. *Lancet Neurol*. 2020 Oct 1;19(10):814-25. [https://doi.org/10.1016/S1474-4422\(20\)30279-9](https://doi.org/10.1016/S1474-4422(20)30279-9)
41. Ferrari MD, Diener HC, Ning X, Galic M, Cohen JM, Yang R, et al. Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial. *Lancet*. 2019 Sep 21;394(10203):1030-40. [https://doi.org/10.1016/S0140-6736\(19\)31946-4](https://doi.org/10.1016/S0140-6736(19)31946-4)
42. Cision [Internet]. Lundbeck reports positive results for Vyepti[®] (eptinezumab) from the DELIVER study in patients with migraine and prior preventive treatment failures. News Powered by Cision; 2021 Nov 1 [cited 2022 Mar 13]. Available from: https://news.cision.com/h-lundbeck-a-s/r/lundbeck-reports-positive-results-for-vyepti---eptinezumab--from-the-deliver-study-in-patients-with-_-c3443462
43. Alpuente A, Gallardo VJ, Caronna E, Torres-Ferrús M, Pozo-Rosich P. Partial and nonresponders to OnabotulinumtoxinA can benefit from anti-CGRP monoclonal antibodies preventive treatment: a real-world evidence study. *Eur J Neurol*. 2021 Jul;28(7):2378-82. <https://doi.org/10.1111/ene.14828>
44. Ailani J, Pearlman E, Zhang Q, Nagy AJ, Schuh K, Aurora SK. Positive response to galcanezumab following treatment failure to OnabotulinumtoxinA in patients with migraine: post hoc analyses of three randomized double-blind studies. *Eur J Neurol*. 2020 Mar;27(3):542-9. <https://doi.org/10.1111/ene.14102>
45. Hepp Z, Bloudek LM, Varon SF. Systematic review of migraine prophylaxis adherence and persistence. *J Manag Care Pharm*. 2014 Jan;20(1):22-33. <https://doi.org/10.18553/jmcp.2014.20.1.22>
46. Winner PK, Spierings ELH, Yeung PP, Aycardi E, Blankenbiller T, Grozinski-Wolff M, et al. Early onset of efficacy with fremanezumab for the preventive treatment of chronic migraine. *headache*. 2019 Nov 1;59(10):1743-52. <https://doi.org/10.1111/head.13654>
47. Winner PK, McAllister P, Chakhava G, Ailani J, Ettrup A, Josiassen MK, et al. Effects of intravenous eptinezumab vs placebo on headache pain and most bothersome symptom when initiated during a migraine attack: a randomized clinical trial. *JAMA*. 2021 Jun 15;325(23):2348-56. <https://doi.org/10.1001/jama.2021.7665>
48. Russell FA, King R, Smillie S-J, Kodji X, Brain SD. Calcitonin gene-related peptide: physiology and pathophysiology. *Physiol Rev*. 2014 Oct 1;94(4):1099-142. <https://doi.org/10.1152/physrev.00034.2013>
49. Mullin K, Kudrow D, Croop R, Lovegren M, Conway CM, Coric V, et al. Potential for treatment benefit of small molecule CGRP receptor antagonist plus monoclonal antibody in migraine therapy. *Neurology*. 2020 May 19;94(20):e2121-5. <https://doi.org/10.1212/WNL.0000000000008944>
50. Deng H, Li G-G, Nie H, Feng Y-Y, Guo G-Y, Guo W-L, et al. Efficacy and safety of calcitonin-gene-related peptide binding monoclonal antibodies for the preventive treatment of episodic migraine - an updated systematic review and meta-analysis. *BMC Neurol*. 2020 Feb 15;20(1):57. <https://doi.org/10.1186/s12883-020-01633-3>
51. Stauffer VL, Wang S, Bonner J, Kim B, Bhandari R, Day KA, et al. Evaluation of injection-site-related adverse events with galcanezumab: a post hoc analysis of phase 3 studies in participants with migraine. *BMC Neurol*. 2020 May 19;20(1):194. <https://doi.org/10.1186/s12883-020-01775-4>
52. Ashina M, Kudrow D, Reuter U, Dolezil D, Silberstein S, Tepper SJ, et al. Long-term tolerability and nonvascular safety of erenumab, a novel calcitonin gene-related peptide receptor antagonist for prevention of migraine: a pooled analysis of four placebo-controlled trials with long-term extensions. *Cephalalgia*. 2019 Dec 1;39(14):1798-808. <https://doi.org/10.1177/0333102419888222>
53. Sun H, Dodick DW, Silberstein S, Goadsby PJ, Reuter U, Ashina M, et al. Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial. *Lancet Neurol*. 2016 Apr 1;15(4):382-90. [https://doi.org/10.1016/S1474-4422\(16\)00019-3](https://doi.org/10.1016/S1474-4422(16)00019-3)

54. Baker B, Schaeffler B, Hirman J, Hompesch M, Pederson S, Smith J. Tolerability of eptinezumab in overweight, obese or type 1 diabetes patients. *Endocrinol Diabetes Metab*. 2021 Feb 2;4(2):e00217. <https://doi.org/10.1002/edm.2.217>
55. Saely S, Croteau D, Jawidzik L, Brinker A, Kortepeter C. Hypertension: a new safety risk for patients treated with erenumab. *Headache*. 2021 Jan 10;61(1):202-8. <https://doi.org/10.1111/head.14051>
56. Kudrow D, Pascual J, Winner PK, Dodick DW, Tepper SJ, Reuter U, et al. Vascular safety of erenumab for migraine prevention. *Neurology*. 2020 Feb 4;94(5):e497-510. <https://doi.org/10.1212/WNL.00000000000008743>
57. Dodick DW, Tepper SJ, Ailani J, Pannacciulli N, Navetta MS, Loop B, et al. Risk of hypertension in erenumab-treated patients with migraine: analyses of clinical trial and postmarketing data. *Headache*. 2021 Oct;61(9):1411-20. <https://doi.org/10.1111/head.14208>
58. Reuter U, Ehrlich M, Gendolla A, Heinze A, Klatt J, Wen S, et al. Erenumab versus topiramate for the prevention of migraine - a randomised, double-blind, active-controlled phase 4 trial. *Cephalalgia*. 2022 Feb 1;42(2):108-18. <https://doi.org/10.1177/03331024211053571>
59. Kowacs F, Roesler CAP, Piovesan ÉJ, Sarmiento EM, Campos HC, Maciel JA Jr, et al. Consensus of the Brazilian Headache Society on the treatment of chronic migraine. *Arq Neuropsiquiatr*. 2019 Jul 29;77(7):509-20. <https://doi.org/10.1590/0004-282X20190078>
60. Agostoni EC, Barbanti P, Calabresi P, Colombo B, Cortelli P, Frediani F, et al. Current and emerging evidence-based treatment options in chronic migraine: a narrative review. *J Headache Pain*. 2019 Aug 30;20(1):92. <https://doi.org/10.1186/s10194-019-1038-4>
61. Lu J, Zhang Q, Guo X, Liu W, Xu C, Hu X, et al. Calcitonin gene-related peptide monoclonal antibody versus botulinum toxin for the preventive treatment of chronic migraine: evidence from indirect treatment comparison. *Front Pharmacol*. 2021 May 3;12:631204. <https://doi.org/10.3389/fphar.2021.631204>
62. Herd CP, Tomlinson CL, Rick C, Scotton WJ, Edwards J, Ives NJ, et al. Cochrane systematic review and meta-analysis of botulinum toxin for the prevention of migraine. *BMJ Open*. 2019 Jul 16;9(7):e027953. <https://doi.org/10.1136/bmjopen-2018-027953>
63. Pijpers JA, Kies DA, Louter MA, van Zwet EW, Ferrari MD, Terwindt GM. Acute withdrawal and botulinum toxin A in chronic migraine with medication overuse: a double-blind randomized controlled trial. *Brain*. 2019 May 1;142(5):1203-14. <https://doi.org/10.1093/brain/awz052>
64. Ali A. Delay in OnabotulinumtoxinA treatment during the COVID-19 pandemic-perspectives from a virus hotspot. *Headache*. 2020 Jun;60(6):1183-6. <https://doi.org/10.1111/head.13830>
65. Gonzalez-Martinez A, Planchuelo-Gómez Á, Guerrero ÁL, García-Azorín D, Santos-Lasaosa S, Navarro-Pérez MP, et al. Effects of the OnabotulinumtoxinA follow-up delay in migraine course during the COVID-19 lockdown. *Neurol Sci*. 2021 Dec;42(12):5087-92. <https://doi.org/10.1007/s10072-021-05180-8>
66. GBD 2016 Headache Collaborators. Global, regional, and national burden of migraine and tension-type headache, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet Neurol*. 2018 Nov 1;17(11):P954-76. [https://doi.org/10.1016/S1474-4422\(18\)30322-3](https://doi.org/10.1016/S1474-4422(18)30322-3)
67. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet*. 2018 Nov 10;392(10159):P1789-858. [https://doi.org/10.1016/S0140-6736\(18\)32279-7](https://doi.org/10.1016/S0140-6736(18)32279-7)
68. Bonafede M, Sapra S, Shah N, Tepper S, Cappell K, Desai P. Direct and indirect healthcare resource utilization and costs among migraine patients in the United States. *Headache*. 2018 May;58(5):700-14. <https://doi.org/10.1111/head.13275>
69. Diener H-C, Holle D, Solbach K, Gaul C. Medication-overuse headache: risk factors, pathophysiology and management. *Nat Rev Neurol*. 2016 Oct;12(10):575-83. <https://doi.org/10.1038/nrneuro.2016.124>
70. Raggi A, Leonardi M, Sansone E, Curone M, Grazi L, D'Amico D. The cost and the value of treatment of medication overuse headache in Italy: a longitudinal study based on patient-derived data. *Eur J Neurol*. 2020 Jan;27(1):62-e1. <https://doi.org/10.1111/ene.14034>
71. Stewart WF, Wood GC, Manack A, Varon SF, Buse DC, Lipton RB. Employment and work impact of chronic migraine and episodic migraine. *J Occup Environ Med*. 2010 Jan;52(1):8-14. <https://doi.org/10.1097/JOM.0b013e3181c1dc56>
72. Shimizu T, Sakai F, Miyake H, Sone T, Sato M, Tanabe S, et al. Disability, quality of life, productivity impairment and employer costs of migraine in the workplace. *J Headache Pain*. 2021 Apr 21;22(1):29. <https://doi.org/10.1186/s10194-021-01243-5>
73. Seddik AH, Schiener C, Ostwald DA, Schramm S, Huels J, Katsarava Z. Social impact of prophylactic migraine treatments in Germany: a state-transition and open cohort approach. *Value Health*. 2021 Oct 1;24(10):1446-53. <https://doi.org/10.1016/j.jval.2021.04.1281>
74. Oliveira AB, Queiroz LP, Rocha-Filho PS, Sarmiento EM, Peres MF. Annual indirect costs secondary to headache disability in Brazil. *Cephalalgia*. 2020 May;40(6):597-605. <https://doi.org/10.1177/0333102419889357>
75. Buse DC, Fanning KM, Reed ML, Murray S, Dumas PK, Adams AM, et al. Life with migraine: effects on relationships, career, and finances from the chronic migraine epidemiology and outcomes (CaMEO) study. *Headache*. 2019 Sep;59(8):1286-99. <https://doi.org/10.1111/head.13613>
76. Martelletti P, Schwedt TJ, Lanteri-Minet M, Quintana R, Carboni V, Diener H-C, et al. My Migraine Voice survey: a global study of disease burden among individuals with migraine for whom preventive treatments have failed. *J Headache Pain*. 2018 Nov 27;19(1):115. <https://doi.org/10.1186/s10194-018-0946-z>
77. Buse DC, Scher AI, Dodick DW, Reed ML, Fanning KM, Adams AM, et al. Impact of migraine on the family: perspectives of people with migraine and their spouse/domestic partner in the CaMEO study. *Mayo Clin Proc*. 2016 Apr 25;S0025-6196(16):00126-9. <https://doi.org/10.1016/j.mayocp.2016.02.013>
78. Buse DC, Powers SW, Gelfand AA, VanderPluym JH, Fanning KM, Reed ML, et al. Adolescent perspectives on the burden of a parent's migraine: results from the CaMEO study. *Headache*. 2018 Apr;58(4):512-24. <https://doi.org/10.1111/head.13254>
79. Sussman M, Benner J, Neumann P, Menzin J. Cost-effectiveness analysis of erenumab for the preventive treatment of episodic and chronic migraine: results from the US societal and payer perspectives. *Cephalalgia*. 2018 Sep 1;38(10):1644-57. <https://doi.org/10.1177/0333102418796842>
80. Mahon R, Lang A, Vo P, Huels J, Cooney P, Danyliv A, et al. Cost-effectiveness of erenumab for the preventive treatment of migraine in patients with prior treatment failures in Sweden. *Pharmacoeconomics*. 2021 Mar;39(3):357-72. <https://doi.org/10.1007/s40273-020-00996-2>